2. Search Result
Search Result
Results for "

pancreatic islets

" in MedChemExpress (MCE) Product Catalog:

45

Inhibitors & Agonists

8

Biochemical Assay Reagents

11

Peptides

1

Inhibitory Antibodies

9

Natural
Products

3

Isotope-Labeled Compounds

9

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-101020
    Picolinamide

    2-Picolinamide

    		 PARP Metabolic Disease
    Picolinamide (2-Picolinamide) is an inhibitor of Poly(ADP-ribose) synthetase of nuclei from rat pancreatic islet cells .
    Picolinamide
  • HY-P1871A
    Amylin (IAPP), feline TFA

    		Amylin Receptor Metabolic Disease
    Amylin (IAPP), feline TFA is a 37-amino acid polypeptide from feline. Amylin (IAPP), feline TFA is one of the major secretory products of β-cells of the pancreatic islets. Amylin (IAPP), feline TFA is a regulatory peptide, which inhibits insulin and glucagon secretion .
    Amylin (IAPP), feline TFA
  • HY-P10735
    GIP (mouse)

    Gastric inhibitory polypeptide(mouse); GIP(1-42) (mouse)

    		 Insulin Receptor Endocrinology
    GIP (mouse) is a gastrointestinal hormone that is expressed in and secreted from the pancreatic islets and promotes insulin secretion .
    GIP (mouse)
  • HY-12462
    WS3

    		Others Inflammation/Immunology
    WS3?is a novel proliferative molecule that promotes pancreatic β cell proliferation in rodent and human primary islets. WS3?can be used for the research of type 1 diabetes .
    WS3
  • HY-I0352R
    Epiandrosterone (Standard)

    		Endogenous Metabolite Potassium Channel Metabolic Disease Endocrinology
    Epiandrosterone (Standard) is the analytical standard of Epiandrosterone. This product is intended for research and analytical applications. Epiandrosterone is a steroid hormone. Epiandrosterone activates BKCa. Epiandrosterone inhibits glucose transport and insulin release. Epiandrosterone has weak androgenic activity .
    Epiandrosterone (Standard)
  • HY-I0352
    Epiandrosterone

    3β-Androsterone; trans-Androsterone; iso-Androsterone

    		 Endogenous Metabolite Potassium Channel Metabolic Disease Endocrinology
    Epiandrosterone is a steroid hormone. Epiandrosterone activates BKCa. Epiandrosterone inhibits glucose transport and insulin release. Epiandrosterone has weak androgenic activity .
    Epiandrosterone
  • HY-P1871
    Amylin (IAPP), feline

    		Amylin Receptor Metabolic Disease
    Amylin (IAPP), feline is a 37-amino acid polypeptide from feline. Amylin (IAPP), feline is one of the major secretory products of β-cells of the pancreatic islets. Amylin (IAPP), feline is a regulatory peptide, which inhibits insulin and glucagon secretion .
    Amylin (IAPP), feline
  • HY-101020R
    Picolinamide (Standard)

    2-Picolinamide (Standard)

    		 Reference Standards PARP Metabolic Disease
    Picolinamide (Standard) is the analytical standard of Picolinamide. This product is intended for research and analytical applications. Picolinamide (2-Picolinamide) is an inhibitor of Poly(ADP-ribose) synthetase of nuclei from rat pancreatic islet cells .
    Picolinamide (Standard)
  • HY-P3003
    Cereulide

    		Apoptosis Neurological Disease Inflammation/Immunology
    Cereulide, a toxin depsipeptide, can be produced by Bacillus cereus. Cereulide induces cell apoptosis. Cereulide acts on mitochondria, leading to dysfunction in different organs (liver, pancreatic islet, brain, intestines, etc.) and body systems (immune system and nervous system) .
    Cereulide
  • HY-E70369
    Collagenase H (Recombinant)

    		Biochemical Assay Reagents Others
    Collagenase H Recombinant is able to digest and break down collagen (especially collagen III) in the extracellular matrix (ECM). Collagenase H Recombinant is important in the isolation and function of rat pancreatic islets. Collagenase H Recombinant can be used in tissue engineering and cell culture .
    Collagenase H (Recombinant)
  • HY-174559
    Human PAX4 mRNA

    		mRNA Metabolic Disease
    Human PAX4 mRNA encodes the human paired box 4 (PAX4) protein, a member of the paired box (PAX) family. PAX4 is involved in pancreatic islet development and mouse studies have demonstrated a role for this gene in differentiation of insulin-producing beta cells.
    Human PAX4 mRNA
  • HY-174557
    Human PAX6 mRNA

    		mRNA Metabolic Disease
    Human PAX6 mRNA encodes the human paired box 6 (PAX6) protein, a member of the paired box (PAX) family. PAX6 may play an important role in the development of the eye, nose, central nervous system and pancreas. It is also required for the differentiation of pancreatic islet alpha cells.
    Human PAX6 mRNA
  • HY-103545
    GIP (1-39)

    Gastric inhibitory peptide (1-39) (porcine)

    		 Insulin Receptor Metabolic Disease
    GIP (1-39) (Gastric inhibitory peptide (1-39) (porcine)) is an insulinotropic peptide that stimulats insulin secretion from rat pancreatic islets. GIP (1-39) at 100 nM was able to significantly increase intracellular Ca 2+ concentration ([Ca 2+]i), and capable of enhancing exocytosis .
    GIP (1-39)
  • HY-B0254
    Glipizide
    2 Publications Verification

    CP 28720; K 4024

    		 Potassium Channel Metabolic Disease Cancer
    Glipizide (CP 2872; K 4024)?a potent, orally active and sulfonylurea class anti-diabetic agent and can be used for type 2?diabetes mellitus research but not type 1. Glipizide acts by partially blocking ATP-sensitive potassium?(KATP) channels among β cells of pancreatic islets of Langerhans .
    Glipizide
  • HY-147207C
    Phospholipid-PEG-Biotin (MW 5000)

    		Liposome Others
    Phospholipid-PEG-Biotin (MW 5000) is a phospholipid PEG derivative, can be used for modify liposome and cells surface, and pancreatic islets for cell transplantation. Phospholipid is a class of lipid containing a hydrophilic “head” and two hydrophobic “tails”; PEG is a hydrophilic and water-soluble polymer with low toxicity; Biotin is an enzyme co-factor, can be used for labeling protein .
    Phospholipid-PEG-Biotin (MW 5000)
  • HY-147207D
    Phospholipid-PEG-Biotin (MW 10000)

    		Liposome Others
    Phospholipid-PEG-Biotin (MW 10000) is a phospholipid PEG derivative that has a biotin and a phospholipid bridged by a linear PEG linker. Phospholipid-PEG-Biotin (MW 3400) can interact with avidinylated antibodies. Phospholipid-PEG-Biotin (MW 3400) can be used to modify liposome and cells surface, and pancreatic islets for cell transplantation .
    Phospholipid-PEG-Biotin (MW 10000)
  • HY-147207B
    Phospholipid-PEG-Biotin (MW 3400)

    		Liposome Others
    Phospholipid-PEG-Biotin (MW 3400) is a phospholipid PEG derivative that has a biotin and a phospholipid bridged by a linear PEG linker. Phospholipid-PEG-Biotin (MW 3400) can interact with avidinylated antibodies. Phospholipid-PEG-Biotin (MW 3400) can be used to modify liposome and cells surface, and pancreatic islets for cell transplantation .
    Phospholipid-PEG-Biotin (MW 3400)
  • HY-120287
    L-054522

    		Somatostatin Receptor Endocrinology
    L-054522 is an agonist for somatostatin receptor subtype 2 with Kd of 0.01 nM. L-054522 inhibits growth hormone release from rat primary pituitary cell (IC50=0.05 nM) and glucagon and insulin release from isolated mouse pancreatic islet cell (IC50=0.05 nM and 12 nM) .
    L-054522
  • HY-164684
    Dichlorobenzamil

    3',4'-Dichlorobenzamil; L-594881

    		 Calcium Channel Sodium Channel Na+/Ca2+ Exchanger Others
    Dichlorobenzamil (3',4'-Dichlorobenzamil; L-594881) is an effective Na/Ca exchange inhibitor. Dichlorobenzamil significantly inhibits 45Ca uptake mediated by reverse Na/Ca exchange in pancreatic islet cells (IC50 = 18 μM). Dichlorobenzamil can also block K + channels and voltage-sensitive Ca 2+ channels .
    Dichlorobenzamil
  • HY-147207E
    Phospholipid-PEG-Biotin (MW 20000)

    		Liposome Others
    Phospholipid-PEG-Biotin (MW 20000) is a phospholipid PEG derivative that has a biotin and a phospholipid bridged by a linear PEG linker. Phospholipid-PEG-Biotin (MW 3400) can interact with avidinylated antibodies. Phospholipid-PEG-Biotin (MW 3400) can be used to modify liposome and cells surface, and pancreatic islets for cell transplantation .
    Phospholipid-PEG-Biotin (MW 20000)
  • HY-147207
    Phospholipid-PEG-Biotin (MW 1000)

    		Liposome Others
    Phospholipid-PEG-Biotin (MW 1000) is a phospholipid PEG derivative that has a biotin and a phospholipid bridged by a linear PEG linker. Phospholipid-PEG-Biotin (MW 3400) can interact with avidinylated antibodies. Phospholipid-PEG-Biotin (MW 3400) can be used to modify liposome and cells surface, and pancreatic islets for cell transplantation .
    Phospholipid-PEG-Biotin (MW 1000)
  • HY-147207A
    Phospholipid-PEG-Biotin (MW 2000)

    		Liposome Others
    Phospholipid-PEG-Biotin (MW 2000) is a Biotin labeled phospholipid PEG derivative, can be used for modify liposome and cells surface, and pancreatic islets for cell transplantation. Phospholipid is a class of lipid containing a hydrophilic “head” and two hydrophobic “tails”; PEG is a hydrophilic and water-soluble polymer with low toxicity; Biotin is an enzyme co-factor, can be used for labeling protein .
    Phospholipid-PEG-Biotin (MW 2000)
  • HY-174547
    Human PDX1 mRNA

    		mRNA Metabolic Disease
    Human PDX1 mRNA encodes the human pancreatic and duodenal homeobox 1 (PDX1) protein, a transcriptional activator of several genes, including insulin, somatostatin, glucokinase, islet amyloid polypeptide, and glucose transporter type 2. PDX1 may be involved in the early development of the pancreas. It also plays a major role in glucose-dependent regulation of insulin gene expression.
    Human PDX1 mRNA
  • HY-P10341
    ZP3022

    		GCGR Metabolic Disease
    ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and gastrin that has the ability to sustainably improve glycemic control. Additionally, ZP3022 can effectively increase β-cell mass, promote β-cell proliferation, and enhance the function of pancreatic islets. ZP3022 can be used in anti-diabetic research .
    ZP3022
  • HY-P3608
    [Des-His1,Glu9] Glucagon

    		GCGR Metabolic Disease
    [Des-His1,Glu9] Glucagon is a potent glucagon receptor system peptide antagonist. [Des-His1,Glu9] Glucagon enhances the glucose-stimulated release of insulin from pancreatic islet cells. [Des-His1,Glu9] Glucagon can be used to research diabetes .
    [Des-His1,Glu9] Glucagon
  • HY-B0254S
    Glipizide-d11

    		Isotope-Labeled Compounds Potassium Channel Metabolic Disease
    Glipizide-d11 is the deuterium labeled Glipizide. Glipizide (CP 2872; K 4024)?a potent, orally active and sulfonylurea class anti-diabetic agent and can be used for type 2?diabetes mellitus research but not type 1. Glipizide acts by partially blocking ATP-sensitive potassium?(KATP) channels among β cells of pancreatic islets of Langerhans .
    Glipizide-d11
  • HY-B0254R
    Glipizide (Standard)

    CP 28720 (Standard); K 4024 (Standard)

    		 Reference Standards Potassium Channel Metabolic Disease
    Glipizide (Standard) is the analytical standard of Glipizide. This product is intended for research and analytical applications. Glipizide (CP 2872; K 4024) a potent, orally active and sulfonylurea class anti-diabetic agent and can be used for type 2 diabetes mellitus research but not type 1. Glipizide acts by partially blocking ATP-sensitive potassium (KATP) channels among β cells of pancreatic islets of Langerhans .
    Glipizide (Standard)
  • HY-N9914
    D-Psicose

    		p38 MAPK NF-κB Metabolic Disease
    D-psicose is an orally active rare sugar. D-psicose inhibits p38-MAPK phosphorylation and MCP-1 expression. D-psicose inhibits the AGEs/RAGE/NF-κB pathway. D-psicose protects pancreatic β-islets, improves hyperglycemia and high-fat diet-induced non-alcoholic fatty liver disease .
    D-Psicose
  • HY-12185
    BRD7389
    1 Publications Verification

    		 Ribosomal S6 Kinase (RSK) Metabolic Disease Cancer
    BRD7389 is a specific RSK family kinase inhibitor with IC50s of 1.5 μM, 2.4 μM, and 1.2 μM for RSK1, RSK2, and RSK3, respectively. BRD7389 is a small-molecule inducer of insulin expression in pancreatic α-cells .
    BRD7389
  • HY-N7241
    Saudin

    		Others Endocrinology
    Saudin, derived from Clutia lanceolata, is a hypoglycemic compound that significantly enhances glucose-triggered insulin release from murine pancreatic islets. It belongs to a group of new diterpenoids with a distinct tetracyclic core, suggesting potential as a therapeutic agent for diabetes treatment. Proposed biosynthetic pathways outline alternative cyclization routes from a common precursor, with Lanceolide P (16) identified as a promising lead compound for further development in managing diabetes .
    Saudin
  • HY-P0262
    Galantide

    		Neuropeptide Y Receptor Neurological Disease Metabolic Disease Inflammation/Immunology Endocrinology
    Galantide, a non-specific galanin receptor antagonist, is a peptide consisting of fragments of galanin and substance P. Galantide recognizes two classes of galanin binding sites (KD<0.1 nM and ~6 nM) in the rat hypothalamus. Galantide dose dependently (IC50=1.0 nM) antagonizes the galanin-mediated inhibition of the glucose-induced insulin secretion from mouse pancreatic islets. Galantide appears to bind to a single population of SP receptors (KD~40 nM) .
    Galantide
  • HY-N9914S
    D-Psicose-d

    		Isotope-Labeled Compounds p38 MAPK NF-κB Metabolic Disease
    D-Psicose-d is the deuterium labeled D-Psicose (HY-N9914). D-psicose is an orally active rare sugar. D-psicose inhibits p38-MAPK phosphorylation and MCP-1 expression. D-psicose inhibits the AGEs/RAGE/NF-κB pathway. D-psicose protects pancreatic β-islets, improves hyperglycemia and high-fat diet-induced non-alcoholic fatty liver disease .
    D-Psicose-d
  • HY-B0481
    Miglitol
    2 Publications Verification

    BAY1099; BAY-m1099

    		 Glycosidase AMPK Reactive Oxygen Species (ROS) Metabolic Disease
    Miglitol (BAY-m1099) is an orally active antidiabetic compound that inhibits the breakdown of glycoconjugates into glucose. Miglitol inhibits glycoside hydrolase enzymes called α-glucosidases. Miglitol inhibits oxidative stress-induced apoptosis and mitochondrial ROS over-production in endothelial cells by enhancement of AMP-activated protein kinase. Dietary supplementation with Miglitol from pre-onset stage in OLETF rats delays the onset and development of diabetes and preserves the insulin secretory function of pancreatic islets .
    Miglitol
  • HY-115403
    FKGK18
    1 Publications Verification

    		 Phospholipase Apoptosis Metabolic Disease
    FKGK18 is a selective group VIA calcium-independent phospholipase A2 (GVIA iPLA2) inhibitor. FKGK18 is a fluoroketone (FK)-based compound with IC50s of 50 nM and 3 μM for iPLA2β and iPLA2γ. FKGK18 can be used for the research of beta-cell apoptosis and diabetes .
    FKGK18
  • HY-13981
    Ligandrol
    2 Publications Verification

    LGD-4033

    		 Androgen Receptor Apoptosis Insulin Receptor Caspase Metabolic Disease Endocrinology
    Ligandrol is an orally active, selective androgen receptor (AR) agonist. Ligandrol enhances protein synthesis, inhibits muscle breakdown and oxidative stress, improves muscle cell viability and bone tissue microstructure, and reduces Cisplatin (HY-17394)-induced muscle toxicity and apoptosis. Ligandrol promotes muscle growth, protects bone structure, and has anti-diabetic, anti-apoptotic and antioxidant effects. Ligandrol can antagonize Streptozotocin (HY-13753) damage to pancreatic islets and improve the symptoms of type 2 diabetes .
    Ligandrol
  • HY-N9914R
    D-Psicose (Standard)

    		Reference Standards p38 MAPK NF-κB Metabolic Disease
    D-Psicose (Standard) is the analytical standard of D-Psicose (HY-N9914). This product is intended for research and analytical applications. D-psicose is an orally active rare sugar. D-psicose inhibits p38-MAPK phosphorylation and MCP-1 expression. D-psicose inhibits the AGEs/RAGE/NF-κB pathway. D-psicose protects pancreatic β-islets, improves hyperglycemia and high-fat diet-induced non-alcoholic fatty liver disease .
    D-Psicose (Standard)
  • HY-N0058
    4,5-Dicaffeoylquinic acid
    Maximum Cited Publications
    7 Publications Verification

    Isochlorogenic acid C

    		 HBV Endogenous Metabolite Apoptosis Glycosidase Infection
    4,5-Dicaffeoylquinic acid (Isochlorogenic acid C) is an antioxidant, can be isolated from Gynura divaricata and Laggera alata. 4,5-Dicaffeoylquinic acid reduces islet cell apoptosis and improves pancreatic function in type 2 diabetic mice, and has obvious inhibitory activities against yeast α-glucosidase. 4,5-Dicaffeoylquinic acid inhibits prostate cancer cells through cell cycle arrest. 4,5-Dicaffeoylquinic acid also has anti-apoptotic, anti-injury and anti-hepatitis B virus effects .
    4,5-Dicaffeoylquinic acid
  • HY-139792
    Besigliptin tosylate

    SHR117887

    		 Endogenous Metabolite Metabolic Disease
    Besigliptin tosylate (SHR117887) is a DPP-4 inhibitor with activity to improve metabolic control and β-cell function. Besigliptin tosylate can effectively reduce serum DPP-4 activity and improve oral glucose tolerance. Besigliptin tosylate significantly reduces fasting blood glucose levels and improves lipid profiles in a diabetic mouse model. The effect of besigliptin tosylate is comparable to that of the known compound vildagliptin (HY-14291) at the same concentration. Besigliptin tosylate increases insulin staining of pancreatic islet cells in chronic administration, indicating improved β-cell function .
    Besigliptin tosylate
  • HY-N0058R
    4,5-Dicaffeoylquinic acid (Standard)

    Isochlorogenic acid C (Standard)

    		 Reference Standards HBV Endogenous Metabolite Apoptosis Glycosidase Infection
    4,5-Dicaffeoylquinic acid (Standard) is the analytical standard of 4,5-Dicaffeoylquinic acid. This product is intended for research and analytical applications. 4,5-Dicaffeoylquinic acid (Isochlorogenic acid C) is an antioxidant, can be isolated from Gynura divaricata and Laggera alata. 4,5-Dicaffeoylquinic acid reduces islet cell apoptosis and improves pancreatic function in type 2 diabetic mice, and has obvious inhibitory activities against yeast α-glucosidase. 4,5-Dicaffeoylquinic acid inhibits prostate cancer cells through cell cycle arrest. 4,5-Dicaffeoylquinic acid also has anti-apoptotic, anti-injury and anti-hepatitis B virus effects .
    4,5-Dicaffeoylquinic acid (Standard)
  • HY-113513
    5-HEPE

    		Others Cancer
    5(S)-HEPE is an active metabolite of eicosapentaenoic acid. It is formed from EPA by 5-lipoxygenase (5-LO). 5(S)-HEPE is an agonist of G protein-coupled receptor 119 (GPR119). It increases cAMP accumulation in CHO-K1 cells expressing human GPR119 when used at a concentration of 10 μM. 5(S)-HEPE increases glucose-induced insulin secretion from MING6 insulinoma pancreatic islets and glucagon-like peptide 1 (GLP-1) secretion from HuTu 80 adenocarcinoma cells when used at a concentration of 10 μM. Serum levels of 5(S)-HEPE are elevated in patients with hyperlipidemia.
    5-HEPE
  • HY-P990254
    Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173)

    		CXCR Inflammation/Immunology Cancer
    Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) is an anti-mouse CXCR3/CD183 IgG monoclonal antibody. Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) weakens the immune response by reducing the infiltration of CD4 + and CD8 + T cells. Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) significantly prolongs the survival time of heart or islet transplants in mice. Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) can be used for researches on immunology and cancer such as pancreatic cancer .
    Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173)
  • HY-P11043
    GEP44

    		GLP Receptor Neuropeptide Y Receptor Arrestin Metabolic Disease
    GEP44 is a peptide biased triple agonist targeting Glucagon-like peptide 1 receptor (GLP-1R), neuropeptide Y1 Receptor (Y1-R), and neuropeptide Y2 Receptor (Y2-R). GEP44 induces Y1-R antagonist-controlled, GLP-1R-dependent stimulation of insulin secretion in both rat and human pancreatic islets by counteracting effects of Y1-R and GLP-1R agonism. GEP44 promotes insulin-independent Y1-R-mediated glucose uptake in muscle tissue and significantly reduces food intake and body weight in diet-induced obese rat models. GEP44 can be used for obesity and type 2 diabetes mellitus research .
    GEP44
  • HY-176745
    SW016789

    		VDAC Metabolic Disease Endocrinology
    SW016789 is a hypersecretion-inducer targeting VDAC1. SW016789 can induce insulin hypersecretion and Ca 2+ influx in β-cells directly. SW016789 induces a transient endoplasmic reticulum stress response (ER stress), but does not cause beta cell death. SW016789 has reversible and non-apoptotic characteristics. SW016789 can be used for the study of Diabetes mellitus type 2 (T2DM) β-cell dysfunction .
    SW016789
  • HY-132184
    5,6-Epoxyeicosatrienoic acid

    5,6-EET; (±)5,6-EpETrE

    		 Adrenergic Receptor Calcium Channel Endocrinology
    5,6-Epoxyeicosatrienoic acid (5,6-EET; (±)5,6-EpETrE) is a fully racemic version of the enantiomeric forms biosynthesized from arachidonic acid by cytochrome P450 enzymes. In solution, 5,6-Epoxyeicosatrienoic acid degrades into 5,6-DiHET and 5,6-δ-lactone, which can be converted to 5,6-DiHET and quantified by GC-MS. In neuroendocrine cells, such as the anterior pituitary and pancreatic islets, 5,6-Epoxyeicosatrienoic acid has been implicated in the mobilization of calcium and hormone secretion. 5,6-Epoxyeicosatrienoic acid is an inhibitor of T-type voltage-gated calcium channels (Cav3) that inhibits isoforms Cav3.1, Cav3.2 (IC50=0.54 μM), and Cav3. and decreases nifedipine-resistant phenylephrine-induced vasoconstriction in isolated mouse mesenteric arteries via Cav3.2 blockade when used at a concentration of 3 μM. In addition, it is a substrate of COX-1 and COX-2.
    5,6-Epoxyeicosatrienoic acid
  • HY-132184S
    5,6-Epoxyeicosatrienoic acid-d11

    5,6-EET-d11; (±)5,6-EpETrE-d11

    		 Isotope-Labeled Compounds Adrenergic Receptor Endocrinology
    5,6-Epoxyeicosatrienoic acid-d11 (5,6-EET-d11) is deuterium labeled 5,6-Epoxyeicosatrienoic acid. 5,6-Epoxyeicosatrienoic acid (5,6-EET; (±)5,6-EpETrE) is a fully racemic version of the enantiomeric forms biosynthesized from arachidonic acid by cytochrome P450 enzymes. In solution, 5,6-Epoxyeicosatrienoic acid degrades into 5,6-DiHET and 5,6-δ-lactone, which can be converted to 5,6-DiHET and quantified by GC-MS. In neuroendocrine cells, such as the anterior pituitary and pancreatic islets, 5,6-Epoxyeicosatrienoic acid has been implicated in the mobilization of calcium and hormone secretion. 5,6-Epoxyeicosatrienoic acid is an inhibitor of T-type voltage-gated calcium channels (Cav3) that inhibits isoforms Cav3.1, Cav3.2 (IC50=0.54 μM), and Cav3. and decreases nifedipine-resistant phenylephrine-induced vasoconstriction in isolated mouse mesenteric arteries via Cav3.2 blockade when used at a concentration of 3 μM. In addition, it is a substrate of COX-1 and COX-2, as measured by oxygen consumption and product formation assays when used at a concentration of 50 μM. (±)5,6-Epoxyeicosatrienoic acid is provided as a mixture of the free acid and lactone .
    5,6-Epoxyeicosatrienoic acid-d11

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: